MicroRNA-155 在非霍奇金淋巴瘤、新型冠状病毒肺炎患者，或两者共同患者中的表达：一项横断面研究。
Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study.
机构信息
Department of Biology, Sirjan Branch, Islamic Azad University, Sirjan, Iran.
Department of Microbiology, Kerman Branch, Islamic Azad University, Kerman, Iran.
出版信息
Iran J Med Sci. 2023 Jan;48(1):26-34. doi: 10.30476/IJMS.2022.91669.2282.
BACKGROUND
Non-Hodgkin lymphoma (NHL) is the eleventh leading cause of cancer-related death in the world. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL. Up to winter 2021-2022, the death toll caused by the coronavirus disease 2019 (COVID-19) has exceeded 5.6 million worldwide. Possible molecular mechanisms involved in the systemic inflammation, and cytokine storm in COVID-19 patients are still not fully understood. MicroRNA-155 (miR-155) plays a role in the post-transcriptional gene regulation of hematopoiesis, oncogenesis, and inflammation. The present study aimed to evaluate the expression of miR-155 in patients with DLBCL and/or COVID-19.
METHODS
A cross-sectional study was conducted from July to December 2020 in Tehran (Iran) to evaluate the expression of miR-155 in adult patients diagnosed with DLBCL and/or COVID-19. The real-time polymerase chain reaction technique was used to evaluate the expression of miR-155 in the sera of 92 adults who were either healthy or suffering from DLBCL and/or COVID-19. Relative quantification of gene expression was calculated in terms of cycle threshold (Ct) value. Data were analyzed using SPSS software, and P<0.05 was considered statistically significant.
RESULTS
The expression of miR-155 was not associated with the sex or age of the participants. In comparison with healthy individuals (-ΔCt -1.92±0.25), the expression of miR-155 increased in patients with COVID-19 (1.95±0.14), DLBCL (2.25±0.16), or both (4.33±0.65).
CONCLUSION
The expression of miR-155 increased in patients with DLBCL and/or COVID-19.
背景
非霍奇金淋巴瘤（NHL）是全球癌症相关死亡的第十一个主要原因。弥漫性大 B 细胞淋巴瘤（DLBCL）是 NHL 中最常见的类型。截至 2021-2022 年冬季，全球因 2019 年冠状病毒病（COVID-19）而死亡的人数已超过 560 万。COVID-19 患者全身炎症和细胞因子风暴的可能分子机制仍不完全清楚。微小 RNA-155（miR-155）在造血、肿瘤发生和炎症的转录后基因调控中发挥作用。本研究旨在评估 miR-155 在 DLBCL 和/或 COVID-19 患者中的表达。
方法
2020 年 7 月至 12 月在伊朗德黑兰进行了一项横断面研究，以评估诊断为 DLBCL 和/或 COVID-19 的成年患者中 miR-155 的表达。使用实时聚合酶链反应技术评估 92 名成年人（健康或患有 DLBCL 和/或 COVID-19）血清中 miR-155 的表达。基因表达的相对定量是根据循环阈值（Ct）值计算的。使用 SPSS 软件分析数据，P<0.05 为统计学显著。
结果
miR-155 的表达与参与者的性别或年龄无关。与健康个体（-ΔCt-1.92±0.25）相比，COVID-19 患者（1.95±0.14）、DLBCL 患者（2.25±0.16）或两者均有的患者（4.33±0.65）的 miR-155 表达增加。
结论
DLBCL 和/或 COVID-19 患者的 miR-155 表达增加。
Zotero 插件